89% of services while 45% tested for Hepatitis C and 20% had eye checks. Those without institutional follow-up services (35%) mostly referred to general paediatricians (61%), well baby clinics (43%) and general practitioners (46%). Types of follow-up services offered were generally independent of the drugs used by the mothers (71%) but 39% and 67% of services would not provide post-hospital care for amphetamine and cannabis exposed infants (respectively).
Background: Placenta accreta (PA) is an uncommon condition occurring during pregnancy which is characterized by abnormal placentation. This study examines the incidence of PA in Australia and New Zealand (ANZ), and to describe clinical management and outcomes, for women and babies affected by this condition.
Method: A bi-national case-control study using the Australasian Maternity Outcomes Surveillance System was undertaken from 2010-2012. Cases were women giving birth who were diagnosed with PA by either antenatal imaging, at operation or by pathology specimens in ANZ. Controls were two women giving birth immediately prior at same maternity unit.
Results: A total of 295 eligible cases were identified, giving an incidence of 44.6/100,000 women giving birth in ANZ. Data were available for 570 controls. Women with PA were more likely to have a caesarean section (AOR:4.6, 95% CI: 2.7 -7.6) and to be admitted to ICU/HDU (AOR:46.1, 95% CI: 22.3 -95.4). Twothirds (66%) of cases underwent hysterectomy compared with only two controls (0.3%). There were two maternal deaths with case fatality rate of 0.7%. There were 12 perinatal deaths among cases (perinatal death rate 38.7 per 1,000 births) and 10 among controls (perinatal death rate 17.2 per 1,000 births). Babies born to mothers with PA were more likely to be preterm (AOR:5.0 95% CI: 3.2 -7.8), low birthweight: (AOR:5.0, 95% CI: 2.9 -8.4), and admission to NICU: (AOR:4.4, 95% CI: 2.8 -6.9).
Conclusions: PA is associated with major maternal and neonatal morbidity including a very high rate of hysterectomy Background: Very preterm (VPT) infants experience poor postnatal growth relative to intrauterine growth rates. Despite poor growth VPT infants at term equivalent age (TEA) have increased fat mass percentage (%FM) compared with infants born at term. The aim of this study was to assess growth and body composition in VPT infants from 32weeks post-menstrual age.
Method: Growth and body composition were assessed using the PEAPOD Infant Body Composition System to measure %FM and fat free mass (FFM) in VPT infants (n = 100) born before 32weeks gestation and studied at 32-36weeks. Body composition was compared to a control group of preterm infants (PTc) (n = 88) born at 32-36weeks gestation and measured on day 2 to 5 postnatally.
Results: At 32-36weeks, the VPT infants had a significantly greater %FM compared to the PTc group (P = 0.028) resulting in an excess of 13.6%FM at TEA. Absolute FM was also elevated with an excess of 340 g at TEA. At 32-36 weeks the VPT infants had a significantly lower FFM (g) compared to PTc infants (P < 0.001) with a FFM deficit of 819 g at TEA. There was no relationship between %FM and antenatal or postnatal steroid exposure.
Conclusions: Preterm infants accumulate fat rapidly soon after birth. The rapid increase in %FM is predominantly due to increased fat accretion although reduced growth of FFM also contributes to the increased proportion of fat. Interventions directed at improving VPT infant growth must include FFM and %FM outcomes as anthropometric measures such as weight are insufficient indicators of growth outcome. 
CHANGES IN NUTRITION PRACTICES IMPROVE NUTRITIONAL OUTCOMES FOR INFANTS <30 WEEKS

